Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295466 | 0.77 | ERN1 (0.43) | ERN1TDP1CES2CES1MEN1 | |
| SCHEMBL31552000 | 0.77 | PRKDC (0.58) | ERN1PRKDCTDP1KDM4EALDH1A1 | |
| SCHEMBL3986050 | 0.76 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL6744464 | 0.74 | ERN1 (0.57) | ERN1PRKDCKDM4EALDH1A1CES2 | |
| SCHEMBL767476 | 0.74 | ERN1 (0.47) | ERN1PRKDCALDH1A1PTPN1 | |
| SCHEMBL29629103 | 0.74 | ERN1 (0.57) | ERN1PRKDCKDM4EALDH1A1CES2 | |
| SCHEMBL29889978 | 0.74 | ERN1 (0.47) | ERN1PRKDCALDH1A1PTPN1 | |
| SCHEMBL8488887 | 0.74 | ERN1 (0.38) | ERN1PRKDCLMNAPTPN1 | |
| SCHEMBL30829782 | 0.74 | ERN1 (0.42) | ERN1PRKDCTDP1ALDH1A1CES2 | |
| SCHEMBL6557478 | 0.74 | ERN1 (0.42) | ERN1PRKDCTDP1ALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771345-B1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9346825-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| CN-103958524-B | The Er Huan oxazolidone CETP inhibitor condensed | MERCK SHARP & DOHME CORP. (US) | 2016-04-06 | — | — | CN | disclosed |
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME LLC | 2014-12-25 | — | — | US | disclosed |
| US-8871738-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2771345-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| CN-103958524-A | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME | 2014-07-30 | — | — | CN | disclosed |
| EP-2620439-A1 | 8-pyrazinyl-S-spiropyrimidinetrione-oxazinoquinoline derivatives as antibacterial agents | PAH USA 15 LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| WO-2013063217-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20090275536-A1 | Antibacterial Agents | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| US-7557100-B2 | Antibacterial agents | PFIZER INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1971612-A1 | 8-PYRAZINYL-S-SPIROPYRIMIDINETRIONE-OXAZINOQUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Pfizer Products Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1888597-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070197518-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-23 | — | — | US | disclosed |
| WO-2007072151-A1 | 8-PYRAZINYL-S-SPIROPYRIMIDINETRIONE-OXAZINOQUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006120563-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275536-A1 | Antibacterial Agents | CLPP, MRPL21, SPOUT1 | ERN1 1359/4885PRKDC 2417/4885TDP1 3679/4885 |
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | CETP, MTTP, APOB | ERN1 965/4885PRKDC 2407/4885TDP1 770/4885 |
| US-20070197518-A1 | Antibacterial agents | CLPP, MRPL21, SPOUT1 | ERN1 1359/4885PRKDC 2417/4885TDP1 3679/4885 |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | CETP, MTTP, APOB | ERN1 965/4885PRKDC 2407/4885TDP1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.